Target- |
MechanismCell replacements |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date20 Jan 2022 |
100 Clinical Results associated with Hirosaki Lifescience Innovation, Inc.
0 Patents (Medical) associated with Hirosaki Lifescience Innovation, Inc.
100 Deals associated with Hirosaki Lifescience Innovation, Inc.
100 Translational Medicine associated with Hirosaki Lifescience Innovation, Inc.